Imunon reports IMNN-001 boosts anti-tumor T-cell activity in Phase 2 ovarian cancer study
Bitget2026/11/06 14:01- Imunon announced new Phase 2 OVATION 2 data supporting IMNN-001’s survival benefit in newly diagnosed advanced ovarian cancer.
- Patient biopsies showed stronger anti-tumor immune activity with IMNN-001 plus chemotherapy, providing a biological explanation for improved survival versus chemotherapy alone.
- The findings will be presented at the Society for Immunotherapy of Cancer meeting in Phoenix on November 7, 2026.
- The pivotal Phase 3 OVATION 3 trial is enrolling patients to confirm IMNN-001’s safety and survival benefit.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Swiss Franc holds ground as US Dollar consolidates ahead of CPI inflation data
Net profit surges fivefold but masks decline in core business; crypto mining companies' shift to AI poses hidden risks
Marathon Holdings' Q3 net profit reached $632 million, up 413% year-on-year. However, its mining revenue declined by 35%. The company relied on selling 13,500 BTC to pay off debts and is now betting on AI infrastructure, increasing the risk of an imbalanced profit structure.
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Crypto prices
More
